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Introduction
Epidemics of meningitis due to Neisseria meningitidis
serogroup A are reported almost every year from sub-
Saharan African countries, representing more than
600 000 affected individuals in the 1990s alone.1,2 The
case fatality ratio (CFR) is estimated to be 10%, with a
further 10–20% of patients developing neurological
sequelae.3,4 During these epidemics with high numbers
of people with meningitis, over-worked health staff often
need effective, cheap, and easy-to-use antibiotics to
handle the large inﬂux of patients.
Long-acting chloramphenicol (oily suspension) was
ﬁrst proven effective against epidemic meningococcal
meningitis in the mid-1970s,5,6 and has been
recommended by WHO as a regimen of one or two
intramuscular injections since 1995·7 Even though oily
chloramphenicol remains active against N meningitidis
serogroup A8 and is critical for the management of
meningitis epidemics, continuation of the production of
the drug is uncertain, mainly because of the absence of
ﬁnancial market perspectives for this product.9
Alternative antimicrobial drugs with proven efﬁcacy
against N meningitidis include intravenous benzyl-
penicillin, ampicillin, and intravenous or intramuscular
chloramphenicol or ceftriaxone.10 However, protocols
using multiple injections every day are impractical to use
in epidemics and only drugs with simple treatment
schedules provide an alternative to oily chloram-
phenicol. Several studies have shown the efﬁcacy of a
daily dose of ceftriaxone for 4 days in the treatment of
bacterial meningitis.11–14 Short-course protocols could
also be effective because of the pharmacological
properties of ceftriaxone that include a long half-life in
blood (8 h) and in cerebrospinal ﬂuid (CSF; 14 h), as well
as residual amounts in CSF above the minimal
inhibitory concentration of most of the organisms 24–48
h after injection.11,15–18 Short-course protocols have been
tested in two randomised trials. In a study undertaken by
Epicentre in 1995, 47 children aged 2–35 months with
meningococcal meningitis did not show any substantial
difference in clinical failure rates among those receiving
a two-injection regimen of ceftriaxone (9%) or oily
chloramphenicol (8%).19 The second small trial
compared 2 days of ceftriaxone with 6 days of
benzylpenicillin in 36 adults with bacterial meningitis.
Recovery rates were 81% and 95%, respectively, with no
signiﬁcant difference shown.20
We undertook a multicentre, randomised, open-label,
non-inferiority trial comparing the efﬁcacy of short-
course treatment of ceftriaxone with that of oily
chloramphenicol in individuals with meningitis
recruited during an epidemic in Niger in 2003.
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Summary
Background In sub-Saharan Africa in the 1990s, more than 600 000 people had epidemic meningococcal meningitis,
of whom 10% died. The current recommended treatment by WHO is short-course long-acting oily chloramphenicol.
Continuation of the production of this drug is uncertain, so simple alternatives need to be found. We assessed
whether the efﬁcacy of single-dose treatment of ceftriaxone was non-inferior to that of oily chloramphenicol for
epidemic meningococcal meningitis.
Methods In 2003, we undertook a randomised, open-label, non-inferiority trial in nine health-care facilities in Niger.
Participants with suspected disease who were older than 2 months were randomly assigned to receive either
chloramphenicol or ceftriaxone. Primary outcome was treatment failure (deﬁned as death or clinical failure) at 72 h,
measured with intention-to-treat and per-protocol analyses.
Findings Of 510 individuals with suspected disease, 247 received ceftriaxone, 256 received chloramphenicol, and
seven were lost to follow-up. The treatment failure rate at 72 h for the intention-to-treat analysis was 9% (22 patients)
for both drug groups (risk difference 0·3%, 90% CI –3·8 to 4·5). Case fatality rates and clinical failure rates were
equivalent in both treatment groups (14 [6%] ceftriaxone vs 12 [5%] chloramphenicol). Results were also similar for
both treatment groups in individuals with conﬁrmed meningitis caused by Neisseria meningitidis. No adverse side-
effects were reported. 
Interpretation Single-dose ceftriaxone provides an alternative treatment for epidemic meningococcal meningitis—its
efﬁcacy, ease of use, and low cost favour its use. National and international health partners should consider
ceftriaxone as an alternative ﬁrst-line treatment to chloramphenicol for epidemic meningococcal meningitis.
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Methods
Patients
The study was undertaken for 1 month (from March 24
to April 27, 2003) during a meningitis epidemic affecting
Maradi and Zinder regions in eastern Niger. Our main
objective was to compare the clinical effectiveness of one
intramuscular injection of ceftriaxone with that of one
intramuscular injection of oily chloramphenicol in the
treatment of N meningitidis meningitis in an epidemic
context. We tested the hypothesis that treatment
outcome with ceftriaxone was non-inferior to that of
chloramphenicol.
An individual with suspected meningitis was deﬁned
as a person admitted to one of eight peripheral health
centres or to the Zinder regional hospital with sudden
onset of fever or history of fever in the past 24 h
associated with at least one of the following symptoms:
neck stiffness, impaired consciousness, or petechial rash
for patients older than 1 year; or bulging fontanel, axial
hypotonia, upwardly turned gaze, or petechial rash for
patients younger than 1 year. An individual with
conﬁrmed meningitis was deﬁned as having suspected
disease with a CSF white-blood-cell count of more than
50 cells per mL and a biological conﬁrmation of N
meningitidis meningitis by: pathogen identiﬁcation in
the CSF by gram staining, presence of soluble antigens
in the CSF detected by direct agglutination test
(Pastorex, Bio-rad Laboratories, CA, USA), pathogen
identiﬁcation in CSF culture, or detection of bacterial
DNA of pathogen by PCR. Apart from PCR, laboratory
testing was undertaken every day in a study laboratory in
Zinder Hospital, Niger. PCR testing was undertaken at
the CERMES laboratory in Niamey, Niger.
Individuals with suspected meningitis were included
after written informed consent (or oral consent
otherwise) was obtained. Patients were excluded if they
were younger than 2 months, had a known allergy to one
of the two trial drugs, had a recurrent history of
meningitis since the beginning of the epidemic, or
presented with non-reactive coma or cardiovascular
shock. Pregnant and breastfeeding women were also
excluded. Standardised data on clinical signs and
symptoms were recorded at admission and throughout
the follow-up for all patients. The study was approved by
the Ministry of Health of Niger and reviewed by an
independent ethics committee in France (Comité
Consultatif de Protection des Personnes dans Recherche
Biomédicale [CCPPRB], St Germain en Laye, France).
Procedures
At inclusion (0 h), medical doctors who were assigned to
the study obtained CSF samples by lumbar puncture,
undertook a rapid test for malaria diagnosis (Optimal,
Diamed, Switzerland), and randomly assigned patients
to receive either ceftriaxone (100 mg/kg to a maximum
of 4 g, one intramuscular dose) or oily chloramphenicol
(100 mg/kg to a maximum of 3 g, one intramuscular
dose). Because of ﬁeld conditions, our trial was not
masked—the vials had different appearances and the
treating doctors were not masked to which treatment
was given. Block randomisation was done with a
computer-generated list and the treatment group was
allocated with individually sealed envelopes. Principal
investigators undertook the randomisation in Paris
before the trial began. They did not assign patients to
treatment groups in the ﬁeld. A second single dose
(ceftriaxone 75 mg/kg or chloramphenicol 100 mg/kg)
was given after 24–48 h in case of clinical failure, which
was deﬁned as: state of consciousness remaining
severely altered (Glasgow coma score 11 at 24 h
or 13 at 48 h), no improvement in the state of
consciousness since 0 h, appearance or worsened
neurological symptoms since 0 h, repeated or persistent
convulsions, or axillary temperature above 38·5ºC in the
absence of other evident infectious pathological changes.
In case of a positive malaria test, artemisinin-based
combination therapy was given. Steroids were not used. 
Primary outcome was treatment failure, deﬁned by
death or clinical failure (as deﬁned above) at 72 h.
557 individuals assessed
         for eligibility
47 excluded
  17 non-reactive coma
  14 pregnant or breastfeeding
    7 previous antibiotic treatment
    5 younger than 2 months
    2 refused to participate
148 meningococcal
         meningitis
         (per-protocol analysis)
160 meningococcal
         meningitis
         (per-protocol analysis)
256 chloramphenicol
         (intention-to-treat
         analysis)
87 excluded
    7 with no LP
 56 with sterile LP
    4 with S pneumoniae or
        H influenzae
 20 with associated 
        infection
108 excluded
       7 with no LP
    77 with sterile LP
       3 with S pneumoniae or
           H influenzae
     21 with associated 
            infection
   3 lost to follow-up
      (because patients
      had left health facility)
259 chloramphenicol251 ceftriaxone
   4 lost to follow-up
      (because patients
      had left health facility)
247 ceftriaxone
         (intention-to-treat
         analysis)
510 individuals with
         suspected disease
         randomised
Figure: Trial proﬁle
LP=lumbar puncture.
Articles
310 www.thelancet.com Vol 366   July 23, 2005 
Rescue treatment for clinical failure at 72 h was
intravenous ceftriaxone (100 mg/kg per day) for a
minimum of 4 days. Secondary endpoints were: death
within 72 h, clinical sequelae at 72 h (judged on gross
clinical abnormality), and clinical failure between 24 h
and 48 h needing a second injection.
Statistical analysis
The sample size was calculated to show non-inferiority
in the proportion of treatment failure at 72 h in the
ceftriaxone group compared with the oily chloram-
phenicol group, which was based on an estimated
proportion of treatment failure in the chloramphenicol
group of 15% and a difference of less than 10% between
the two groups (beyond which non-inferiority could not
be proven). We needed a sample size of 175 individuals
with conﬁrmed meningococcal meningitis per group to
reject the null hypothesis of inferiority of ceftriaxone to
oily chloramphenicol, if we considered a one-sided 5%
signiﬁcance level, 80% power, and 10% loss to follow-
up.21
Primary and secondary endpoints were analysed
according to intention-to-treat principles (all individuals
with suspected disease included) as well as per-protocol
principles (restricted to individuals with conﬁrmed
meningococcal meningitis without any additional
infection or concomitant antibiotherapy). For each
analysis, differences between groups in the distribution
of baseline characteristics at admission were tested using
the 2 or Fisher’s exact test for categorical variables and
the Mann-Whitney or t test for continuous variables. We
calculated the risk difference and 90% CIs of the primary
and secondary outcomes.21 The difference was regarded
as equivalent if the upper limit of its 90% CI was below
10%.
A separate analysis assessing the risk of treatment
failure at 72 h with suspected meningococcal meningitis
was  undertaken for all baseline characteristics using
univariate and multivariate logistic regression. Data
entry and analyses were undertaken by use of EpiInfo
6.04 (Centers for Disease Control and Prevention,
Atlanta, GA, USA) and SPSS 10·0 (SPSS, Chicago, IL,
USA) software packages. 
Role of the funding source 
MSF was the main source of funding for this study. MSF
staff reviewed the manuscript and provided suggestions
to clarify methods and results. Members of MSF were on
the scientiﬁc committee and participated in the ﬁeld
study. The corresponding author had full access to all
the data in the study and had ﬁnal responsibility for the
decision to submit for publication.
Results
Of the 557 patients screened, 510 were randomly
assigned to receive ceftriaxone or chloramphenicol. Of
these individuals, 47 (9%) were excluded because they
were ineligible and another seven (1%) were lost to
follow-up after treatment allocation (ﬁgure). At the time
of inclusion for the intention-to-treat analysis, 99 (20%)
patients had impaired consciousness and 101 (20%)
reported a history of severe convulsions (table 1). Body
temperature was more than 38°C in 370 (74%) patients.
A rapid test for malaria diagnosis was positive for
45 (9%) of individuals tested.
Rate of treatment failure at 72 h was about 9% both
overall and for ceftriaxone and chloramphenicol
separately (table 2); it was judged equivalent across 
the two treatment groups. Of the 44 treatment 
Intention-to-treat analysis Per-protocol analysis
Chloramphenicol Ceftriaxone Chloramphenicol Ceftriaxone 
Age (years)
5 79 (31%) 81 (33%) 35 (24%) 33 (21%)
5–14 145 (57%) 136 (55%) 96 (65%) 108 (67%)
15 32 (12%) 30 (12%) 17 (11%) 19 (12%)
Median (IQR) 7·0 (4-11) 7·0 (3-10) 7·0 (5-11) 8·0 (5-12)
Sex  (male) 132 (52%) 133 (54%) 67 (45%) 89 (57%)
Duration of fever (h)
Mean (SD) 45·5 (40·4) 42·6 (32·4) 45·5 (35·5) 42·6 (34·9)
48 h 51 (20%) 43 (17%) 29 (20%) 26 (16%)
Temperature 38°C 183 (71%) 187 (76%) 100 (67%) 117 (74%)
Dehydration 22 (9%) 19 (8%) 11 (7%) 15 (10%)
Convulsions
All types 69 (27%) 68 (28%) 29 (20%) 37 (24%)
Severe 47 (19%) 54 (23%) 22 (15%) 30 (19%)
Impaired consciousness 49 (19%) 50 (20%) 24 (16%) 33 (21%)
Glasgow score 12 30 (17%) 23 (14%) 20 (18%) 19 (15%)
(in participants older than 4 years)
Petechial rash 2 (1%) 2 (1%) 1 (1%) 1 (1%)
Positive malaria test result 23 (9%) 22 (9%) 0 0
Cause
N meningitidis 169 (66%) 180 (73%) n/a n/a
S pneumoniae 2 (1%) 2 (1%) n/a n/a
H inﬂuenzae 1 2 (1%) n/a n/a
Negative 77 (30%) 56 (23%) n/a n/a
No lumbar puncture 7 (3%) 7 (3%) n/a n/a
Diagnosis of meningococcal meningitis only 148 (58%) 160 (65%) n/a n/a
Data are number (%) unless indicated otherwise.  Totals differ because of missing values. n/a=not applicable.
Table 1: Baseline characteristics
Overall Chloramphenicol Ceftriaxone Difference % (90% CI)
n (%) Total n (%) Total n (%) Total
Intention-to-treat analysis
Treatment failure at 72 h 44 (9%) 503 22 (9%) 256 22 (9%) 247 0·3% (–3·8 to 4·5)
Death at 72 h 26 (5%) 503 12 (5%) 256 14 (6%) 247 1·0% (–2·3 to 3·8)
Second injection between  35 (7%) 481 19 (8%) 247 16 (7%) 234 –0·9% (–4·7 to 3·0)
24 h and 48 h
Neurological sequelae at 72 h 29 (6%) 477 13 (5%) 244 16 (7%) 233 1·6% (–2·1 to 5·1)
Per-protocol analysis
Treatment failure at 72 h 16 (5%) 308 8 (5%) 148 8 (5%) 160 –0·4% (–4·6 to 3·8)
Death at 72 h 11 (4%) 308 5 (3%) 148 6 (4%) 160 0·4% (–3·1 to 3·8)
Second injection between 20 (7%) 298 9 (6%) 144 11 (7%) 154 0·8% (–3·9 to 5·7)
24 h and 48 h
Neurological sequelae at 72 h   23 (8%) 297 9 (6%) 143 14 (9%) 154 2·8% (–2·3 to 7·9)
Table 2: Proportion of primary and secondary endpoints
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failures at 72 h, 26 were caused by death and 18 by
clinical failure. CFR at 72 h was about 5% in
patients receiving chloramphenicol and 6% in those
receiving ceftriaxone (table 2). Clinical failure took place
in ten (4%) of 244 surviving participants in
the chloramphenicol group and in eight (3%) of 233 in
the ceftriaxone group (difference –0·8%, 90% CI
–3·3 to 2·8). Of the 481 individuals with suspected
disease at 48 h, 35 received a second injection; the re-
injection rate in the chloramphenicol group was similar
to that in the ceftriaxone group. Neurological sequelae
at 72 h were reported in 29 (6%) surviving individuals,
which included hearing impairment (n=14), and motor
dysfunction (ie, ataxia, motor deﬁcit, or both;
n=15; table 2). Proportion of sequelae was comparable
between chloramphenicol and ceftriaxone at about 7%.
In the per-protocol analysis, CSF samples were taken
from 489 of the 503 individuals with suspected disease.
Meningitis was diagnosed in 356 (73%) participants.
Pathogens identiﬁed were: N meningitidis (98%, n=349
samples), Streptococcus pneumoniae (1%, n=4), and
Haemophilus inﬂuenzae (1%, n=3). The 349 patients
with conﬁrmed meningococcal meningitis included 41
(12%) individuals who either presented with an
associated infection at 0 h (n=27 [malaria], n=3
[bronchopneumonia]) or received concomitant
antibiotherapy (n=11) and were excluded from per-
protocol analysis. 
Of the 308 patients with conﬁrmed disease analysed
per protocol, 160 received ceftriaxone and 148 received
chloramphenicol. The distribution of characteristics on
admission did not differ signiﬁcantly between these
groups (table 1). At 72 h, treatment failure was about 5%
overall and in each treatment group. 11 (4%) patients
died before 72 h and ﬁve (2%) of those who survived
were classiﬁed as clinical failure. CFR was judged
equivalent between the two treatment groups (table 2).
The rate of second injection was about 6% in the
chloramphenicol group compared with 7% in the
ceftriaxone group. Of the patients with reported
sequelae, nine (6%) were in the chloramphenicol group
and 14 (9%) in the ceftriaxone group. No serious adverse
events were reported during the study.
Univariate analysis of all individuals with suspected
disease (table 3) showed a strong association between
the risk of treatment failure at 72 h and (1) impaired
consciousness, (2) either no conﬁrmed disease or
meningococcal meningitis associated with another
infection, and (3) severe convulsion before admission.
We did not record any association between ceftriaxone
treatment and risk of treatment failure (odds ratio 1·0,
95% CI 0·6–1·9). However, an association was seen
between the risk of treatment failure for
children younger than 5 years and that for children older
than 14 years, but this relation was not signiﬁcant (3·0,
0·8–10·3; table 3). In the multiple logistic regression
model, only impaired consciousness at 0 h or diagnosis
of another disease (alone or associated with
meningococcal meningitis) remained signiﬁcant risk
factors for treatment failure at 72 h. 
Discussion
Our results suggest non-inferiority of ceftriaxone to
chloramphenicol when used as short-course (single-
dose) treatment against epidemic meningococcal
meningitis. 72 h after admission, we showed equivalency
in the CFR, clinical failure rate, proportion of second
injection, and proportion of sequelae between the
treatment groups. Individuals with suspected disease
represented more than 90% of those attending health
facilities during the study. This exhaustive recruitment
and the multiple inclusion sites (eight primary and one
secondary health facilities) favour a highly representative
sample of the population of individuals with meningitis
who consult peripheral health structures during
epidemics. 
Our study was undertaken in peripheral health
structures during the acute phase of an epidemic.
Because of on-site constraints, the duration of follow-up
was restricted to 72 h after admission, and information
about long-term sequelae could not be extrapolated from
our data. Patients in clinical failure at 72 h were followed
through to complete recovery. Although the risk of
relapse after discharge was regarded as low and all
patients were advised to return to the clinic in the event
Treatment failure at 72 h Univariate analysis (n=503), Multivariate analysis (n=478), 
n (%) Total
odds ratio (95% CI) odds ratio (95% CI)
Sex
Male 25 (9%) 265 1·2 (0·6–2·2) 0·9 (0·5–1·8)
Female 19 (8%) 238 1 1
Age (years)
5 21 (13%) 160 3·0 (0·8–10·3) 1·4 (0·4–5·2)
5–14 20 (7%) 281 1·5 (0·4–5·2) 1·3 (0·3–4·7)
15 3 (5%) 62 1 1
Duration of fever before admission (days)
2 17 (7%) 246 0·6 (0·3–1·2) 0·8 (0·4–1·8)
2 27 (11%) 250 1 1
Temperature (ºC) at admission
39·5 12 (11%) 105 1·8 (0·8–4·1) 1·5 (0·6–3·8)
38·6–39·5 18 (10%) 186 1·5 (0·7–3·1) 2·0 (0·9–4·5)
38·5 14 (7%) 212 1 1
Received antipyretic before admission
Yes 18 (10%) 184 1·2 (0·6–2·2) 1·8 (0·9–3·7)
No 26 (8%) 313 1 1
Dehydration at admission
Yes 4 (10%) 41 1·1 (0·4–3·3) 0·8 (0·2–2·7)
No 40 (9%) 461 1 1
Severe convulsion at or before admission
Yes 17 (17%) 101 2·8 (1·5–5·4) 1·9 (0·9–4·1)
No 26 (7%) 388 1 1
Impaired consciousness at admission
Yes 23 (23%) 99 5·5 (2·9–10·4) 5·0 (2·3–10·6)
No 21 (5%) 403 1 1
Diagnosis of another or meningitis-associated disease
Yes 28 (14%) 195 3·1 (1·6–5·8) 3·3 (1·6–6·8)
No 16 (5%) 308 1 1
Table 3: Risk of treatment failure in individuals with suspected meningitis 
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of clinical deterioration, no patients returned during the
study period. Other studies testing short-course
treatment (2–4 days) of ceftriaxone or chloramphenicol
with longer follow-up periods than ours also failed to
identify individuals with relapsed disease.11–14,22–24 This
scarcity of data could be explained by the fact that CSF is
sterile  24–48 h after one injection of ceftriaxone or
chloramphenicol.11,15–18,25
In both of our treatment groups, the CFR was lower
than those reported from epidemiological surveillance or
prospective studies undertaken during meningitis
epidemics.26–29 This difference might be due to the
exclusion of individuals with the most severe disease and
the study conditions that ensured full-time availability of
medical staff and material. Previous studies have shown
similar CFR and recovery rates without sequelae at 72 h
to those in our study.5,13,14,22,23 All deaths reported in our
study took place within 30 h of admission, and all
occurred in patients who presented with impaired
consciousness at admission. Furthermore, two-thirds of
the patients who died had been diagnosed with another
infection, either alone or associated with meningococcal
meningitis. Unconﬁrmed meningococcal meningitis or
meningitis associated with another infection was one of
the main risk factors for treatment failure at 72 h
(table 3). Our results suggest that during a meningitis
epidemic, if fever persists 48 h after a single injection of
ceftriaxone or chloramphenicol with a second injection of
antibiotics, other diseases such as malaria should be
considered and treated immediately. 
Antimicrobial drugs recommended during meningitis
epidemics in sub-Saharan Africa should also be effective
against other pathogens responsible for bacterial
meningitis, and affordable for these countries.
Resistance of S pneumoniae and H inﬂuenzae to
chloramphenicol is increasing worldwide, but does not
exceed 10% in African countries.30–33 By contrast, only a
few strains of S pneumoniae that are resistant to
ceftriaxone have been isolated in Africa.34,35 The cost of
generic ceftriaxone has rapidly fallen, since patent rights
for this drug expired in most countries. In our study, the
average treatment dose was 2 g per person for both
drugs. Treatment cost per patient was estimated as
US$4–6 for chloramphenicol and $2–3 for ceftriaxone.
In conclusion, ceftriaxone is an equally effective
alternative to oily chloramphenicol for the treatment of
meningococcal meningitis during epidemics in resource-
poor settings. The good efﬁcacy and ease of use in an
epidemic context, effectiveness against pathogens such
as S pneumoniae, wide availability, and low cost are good
arguments for ceftriaxone use. Future production of oily
chloramphenicol is still uncertain. The potential for
emergence of resistance of ceftriaxone if inappropriately
used is a major concern. Public-health authorities should
put mechanisms in place to ensure proper use of
ceftriaxone to avoid rapid spread of resistance as seen
previously with other broad-spectrum antibiotics.
Recommendations for the conditions of ceftriaxone use,
as well as strategies for its introduction and distribution
during epidemics, should now be addressed by national
and international health partners. 
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